智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理

Core Viewpoint - The company Zhifei Biological Products Co., Ltd. has received a clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01, developed by its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. [1] Group 1 - The clinical trial application for the ZFA01 adjuvanted vaccine has been accepted, allowing the company to proceed with clinical trials if no negative or questioning opinions are received within 60 days from the acceptance date [1]